Revisiting the HD 21749 planetary system with stellar activity modelling

HD 21749 is a bright (V = 8.1 mag) K dwarf at 16 pc known to host an inner terrestrial planet HD 21749c as well as an outer sub-Neptune HD 21749b, both delivered by Transiting Exoplanet Survey Satellite (TESS). Follow-up spectroscopic observations measured the mass of HD 21749b to be 22.7 ± 2.2 M with a density of 7.0^{+1.6}_{-1.3} g cm-3, making it one of the densest sub-Neptunes. However, the mass measurement was suspected to be influenced by stellar rotation. Here, we present new high-cadence PFS RV data to disentangle the stellar activity signal from the planetary signal. We find that HD 21749 has a similar rotational time-scale as the planet's orbital period, and the amplitude of the planetary orbital RV signal is estimated to be similar to that of the stellar activity signal. We perform Gaussian process regression on the photometry and RVs from HARPS and PFS to model the stellar activity signal. Our new models reveal that HD 21749b has a radius of 2.86 ± 0.20 R, an orbital period of 35.6133 ± 0.0005 d with a mass of Mb = 20.0 ± 2.7 M and a density of 4.8^{+2.0}_{-1.4} g cm-3 on an eccentric orbit with e = 0.16 ± 0.06, which is consistent with the most recent values published for this system. HD 21749c has an orbital period of 7.7902 ± 0.0006 d, a radius of 1.13 ± 0.10 R, and a 3σ mass upper limit of 3.5 M. Our Monte Carlo simulations confirm that without properly taking stellar activity signals into account, the mass measurement of HD 21749b is likely to arrive at a significantly underestimated error bar

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Stock markets in transition: the Warsaw experiment

This paper investigates the development from 1991 to 1994 of the Warsaw Stock Exchange, which opened on April 16th, 1991. An overview is presented focusing first on the deepening of the equity market, with a still limited but increasing number of listed companies, and then on the high trading activity and price dynamics with their impressive outburst in 1993. Three important dimensions are thereafter analyzed: the relevance of organizational and regulatory choices, the degree of market inefficiency and the origin of the discrepancy between IPO prices and first quoted market prices. Concluding remarks concentrate on the market's ability to fulfil its fundamental tasks. Copyright The European Bank for Reconstruction and Development, 1997.